Patchy distribution of joint inflammation resolved

November 15, 2018

Chronic inflammatory rheumatic diseases such as rheumatoid arthritis (RA) and spondylo-arthritis (SpA) are chronic disabling diseases that have a poor outcome on loco-motoric function, if left untreated. RA en SpA affect each about 1% of the population. The reason why certain joints are more affected than others has been a longstanding question, resolved by Isabelle Cambré and Prof. Dirk Elewaut from the VIB-UGent Center for Inflammation Research who published their results in Nature Communications

They found that biomechanical forces are key drivers behind this observation. By studying the inflammation induced bone erosions in detail they identified certain hot spots in the musculoskeletal system where joint inflammation and erosions are more likely to occur. These sites are especially sensitive to mechanical loading and explain the clinical pattern of joint involvement described in human patients.

The team also discovered the underlying mechanisms, which involves release of certain inflammatory mediators, like chemokines, by joint resident cells in response to mechanical stress. This in turn leads to recruitment of certain white blood subsets, classical monocytes, into mechanically stressed regions where they mediate inflammation and subsequently tissue damage such as erosions.

Isabelle Cambré (VIB-UGent): "Our results explain to a large degree the patchy nature of joint inflammation in human arthritis and the clinical pattern of joint involvement." We are currently trying to unravel the underlying pathways driving this inflammation: we are excited about this as this is potentially a new area of research at the intersection of mechanobiology and inflammation.
-end-
Publication

Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis, Cambré et al., Nature Communications 2018

Questions from patients

A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. That is why we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: patienteninfo@vib.be">patienteninfo@vib.be. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.

Funding

Fonds Wetenschappelijk Onderzoek-Vlaanderen (FWO), Fonds voor Wetenschappelijk Reuma Onderzoek (FWRO)

VIB (the Flanders Institute for Biotechnology)

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.